본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Cholestyramine in hemodialysis: a new approach for hyperphosphatemia management

이용수  0

영문명
발행기관
대한생리학회-대한약리학회
저자명
간행물 정보
『The Korean Journal of Physiology & Pharmacology』제29권 제4호, 465~473쪽, 전체 9쪽
주제분류
의약학 > 의학일반
파일형태
PDF
발행일자
2025.06.30
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

Hyperphosphatemia is a potentially life altering condition in end-stage renal disease patients who are on regular hemodialysis that can lead to cardiovascular calcification, metabolic bone disease and secondary hyperparathyroidism. Bile acid sequestrants are anion exchange resins bind to bile acids and phosphate in the intestine resulting in preventing intestinal absorption of dietary phosphate, interruption of bile acid homeostasis and reduction in low-density lipoprotein cholesterol levels. Cholestyramine is chosen for study in hemodialysis patients based on the effectiveness and safety of bile acid sequestrants such colestilan and colestipol in the treatment of hyperphosphatemia and hypercholesterolemia in hemodialysis patients. A prospective, interventional, randomized, double blinded, placebo-controlled two arm study was carried out to assess the efficacy of oral cholestyramine on reduction of serum phosphate level in adult hemodialysis patients. 76 eligible patients were randomly assigned to either a drug group or a placebo group for the 2-month study period. The protocol was approved by the institutional review board of the faculty of pharmacy Ain Shams University Ethical committee and has been registered on ClinicalTrials.gov: NCT05577507. Over the 2-month treatment period, patients in cholestyramine group showed a significant decline in serum phosphorus levels versus placebo group (4.6 mg/dl vs. 6.6 mg/dl; p < 0.001) and serum calcium–phosphorus product (40 mg2/dl2 vs. 59.8 mg2/dl2; p < 0.001). Median serum triglyceride and low-density lipoprotein cholesterol levels had decreased significantly versus baseline values in the cholestyramine group. Cholestyramine used with phosphate binders effectively lowers phosphorus levels, improves the lipid profile, and has mild adverse effects.

영문 초록

목차

INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

. (2025).Cholestyramine in hemodialysis: a new approach for hyperphosphatemia management. The Korean Journal of Physiology & Pharmacology, 29 (4), 465-473

MLA

. "Cholestyramine in hemodialysis: a new approach for hyperphosphatemia management." The Korean Journal of Physiology & Pharmacology, 29.4(2025): 465-473

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제